Nanobiotix

Nanobiotix presents NBTXR3 preclinical data

Paris, France and Cambridge, Massachusetts, USA, November 14, 2016 - NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces preclinical data demonstrating that its leading radioenhancer nanoparticle, NBTXR3, actively stimulates the host immune system to attack tumor cells. These data from the ongoing NBTXR3 immuno-oncology preclinical program...

Nanobiotix Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relations

Paris, France and Cambridge, Massachusetts, USA October 3, 2016 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has strengthened its U.S. leadership team with the appointments of Dr. Mihail Obrocea as the Head of U.S. Clinical Development and...

Nanobiotix announces that Bpifrance has awarded the company an interest free loan

Paris, France, and Cambridge, Massachusetts, USA, September 19, 2016 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that Bpifrance has awarded the Company an interest-free loan of Ä2M for Innovation (prÍt ‡ taux zÈro pour líInnovation - PTZI). The interest-free...

Nanobiotix half year results for the six months ended 30 June 2016

Nanobiotix releases financial information for the six months ended 30 June 2016, complete with updated shareholder composition
NGIN, 210 Broadway Cambridge, MA02139, US

+33 (1) 40 26 04 70